Trials / Completed
CompletedNCT00402168
A Study of BMS-224818 (Belatacept) in Patients Who Have Undergone a Kidney Transplant and Are Currently on Stable Cyclosporine or Tacrolimus Regimen With or Without Corticosteroids
Belatacept Conversion Trial in Renal Transplantation
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 173 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to learn if conversion to belatacept from cyclosporine or tacrolimus will preserve kidney function in people who have had a kidney transplant. The safety and tolerability of this treatment will also be studied
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Belatacept | IV, IV Infusion, 5 mg/kg once every 28 days for one year |
| DRUG | Cyclosporine A | Tablets, Oral, Trough of 100-250 ng/mL, 2\* daily for one year |
| DRUG | Tacrolimus | Tablets, Oral, Trough of 5-10 ng/mL, 2\* daily for one year |
Timeline
- Start date
- 2007-01-01
- Primary completion
- 2009-06-01
- Completion
- 2013-06-01
- First posted
- 2006-11-22
- Last updated
- 2017-01-05
- Results posted
- 2017-01-05
Locations
44 sites across 12 countries: United States, Argentina, Australia, Belgium, Brazil, Canada, France, Germany, India, Mexico, Poland, Spain
Source: ClinicalTrials.gov record NCT00402168. Inclusion in this directory is not an endorsement.